Defendant
1 case as defendant.
Actavis LLC — Company Profile
Overview. Actavis LLC is a U.S. corporate entity tied to the Actavis generics business. The Actavis name comes from Actavis Group, a Swiss generics maker that Watson Pharmaceuticals, Inc. (Parsippany, New Jersey) acquired in 2012 for roughly $5.9 billion; Watson renamed itself Actavis plc in 2013, redomiciled to Dublin, Ireland, and absorbed Warner Chilcott (2013) and Forest Laboratories (2014) before taking the Allergan plc name in 2015. In July 2015 Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) agreed to buy Allergan's Actavis Generics unit for about $40.5 billion, closing August 2, 2016. The tracked 2016 suit was therefore filed while that business sat inside Allergan and shortly afterward moved to Teva. No headcount or revenue is published separately for Actavis LLC; the combined Watson–Actavis business reported over $8 billion in 2012 revenue and about 17,000 employees.
Operations. Actavis LLC is part of an operating generic-pharmaceutical manufacturer, not a shell or patent-assertion vehicle. The business develops, manufactures and markets generic prescription drugs across oral solid, modified-release, transdermal, semi-solid, liquid and injectable dosage forms, plus active pharmaceutical ingredients, over-the-counter products and biosimilars. Its U.S. pipeline included roughly 180 pending ANDAs, with distribution handled partly through Anda, Inc.
Litigation posture. The case data show zero plaintiff appearances and one defendant appearance: Actavis LLC is a defendant-only Hatch-Waxman target, consistent with an operating company defending its product filings rather than an NPE asserting acquired patents. The single case was filed in the District of New Jersey — Helsinn's favored forum, where its U.S. subsidiary and distributor are based — not in the Eastern District of Texas.
Notable case. Helsinn Healthcare S.A. et al. v. Actavis LLC, No. 2:16-cv-01683 (D.N.J., filed March 24, 2016). Helsinn and Roche Palo Alto alleged that Actavis's submission of NDA No. 208522 (a §505(b)(2) application for generic palonosetron hydrochloride injection) infringed U.S. Patent Nos. 7,947,724 and 9,066,980, covering liquid palonosetron formulations for brand Aloxi. Actavis answered and counterclaimed; the action was stayed pending related action 14-4274 and dismissed by stipulation on May 15, 2019. It belongs to Helsinn's broad New Jersey campaign against generic palonosetron filers (Dr. Reddy's, Sandoz, Teva, Hospira, Sagent, Zydus/Cadila and others); the Teva branch reached the Supreme Court in Helsinn Healthcare S.A. v. Teva (2019) on the AIA on-sale bar.
ANDA action asserting U.S. 7,947,724 and U.S. 9,066,980. Stayed pending resolution of Civil Action No. 14-4274; ended by stipulated dismissal without prejudice after Actavis withdrew its NDA.